OPRX vs. GDRX: Which Health Tech Stock Has Stronger Revenue Momentum?

OptimizeRx (OPRX) reported robust Q1 2025 revenues of $21.9 million, an 11% year-over-year increase, alongside improved profitability and high revenue visibility for FY25, driven by its strategic shift to a subscription model and Digital Audience Activation Platform expansion, resulting in a 166.8% YTD stock surge. In contrast, GoodRx (GDRX) posted Q1 revenues of $202.9 million, up 2.6%, with adjusted EBITDA rising 11%, driven by increased revenue per user despite a decline in monthly active consumers, and its shares are up 2.1% YTD. While OPRX demonstrates stronger revenue momentum and B2B SaaS growth potential, GDRX maintains consumer-focused scale and durability through evolving platform initiatives.

Analysis

A comparative analysis of OptimizeRx (OPRX) and GoodRx (GDRX) reveals two distinct strategic paths in the health tech sector. OPRX is demonstrating significant growth momentum, with Q1 revenues climbing 11% year-over-year to $21.9 million and adjusted EBITDA turning positive at $1.5 million. Critically, the company has secured over 80% of its full-year 2025 revenue guidance under contract, providing high visibility. This performance, driven by its B2B focus on integrating with EHRs and a strategic shift to a subscription model, has propelled its stock up 166.8% year-to-date. Conversely, GoodRx, while operating on a much larger scale with $202.9 million in Q1 revenue, posted modest top-line growth of 2.6%. The company is successfully improving profitability, evidenced by an 11% rise in adjusted EBITDA and a 7% increase in revenue per user, which compensates for a decline in monthly active consumers. Despite its strong brand and cash position, GDRX's stock has grown only 2.1% YTD. The valuation reflects this divergence: OPRX trades at a forward P/S of 2.16x with projected 63.6% EPS growth, while GDRX trades at 2.02x with projected 11.8% EPS growth, indicating the market is pricing in OPRX's superior growth trajectory.

Key Decisions for Investors

• Investors with a higher risk tolerance seeking pure-play growth should consider OptimizeRx, given its strong 11% revenue growth, positive EBITDA inflection, and high revenue visibility, but must be mindful of its 166.8% YTD rally and premium valuation.
• For value-oriented investors focused on scale and profitability, GoodRx may be more suitable due to its substantial revenue base, strong 34.4% EBITDA margin, and lower forward P/S ratio, but progress on reversing its declining user base is a key metric to monitor.
• The primary decision rests on investment thesis: OPRX represents a B2B SaaS growth story with strong momentum, whereas GDRX is a consumer-focused turnaround play dependent on enhancing user monetization and executing new platform initiatives.